Abstract
Coronary atherosclerosis, also termed coronary artery disease (CAD), is the most common type of heart disease and the most frequent cause of acute myocardial infarction. CAD accounts for approximately 15 % of all deaths in the developed nations. Despite the high prevalence (approximately 20 % in people over 60 years of age), a relevant reduction of CAD mortality has been seen in the last decades due to coronary reperfusion strategies, advances in antianginal medical therapy, heart failure treatment, and better control of cardiovascular risk factors.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695
Gibbons RJ, Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM, O’Rourke RA, Pasternak RC, Williams SV (2003) ACC/AHA 2002 guideline update for the management of patients with chronic stable angina. J Am Coll Cardiol 41:159–168
Dumitriu IE, Araguás ET, Baboonian C, Kaski JC (2009) CD4+ CD28 null T cells in coronary artery disease: when helpers become killers. Cardiovasc Res 81:11–19
Neubauer S (2007) The failing heart–an engine out of fuel. N Engl J Med 356:1140–1151
Lee L, Horowitz J, Frenneaux M (2004) Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 25:634–641
Ferrari R, Ceconi C, Curello S, Benigno M, La Canna G, Visioli O (1996) Left ventricular dysfunction due to the new ischemic outcomes: stunning and hibernation. J Cardiovasc Pharmacol 28:S18–S26
Cooper HA, Braunwald E (2001) Clinical importance of stunned and hibernating myocardium. Coron Artery Dis 12:387–392
Yellon DM, Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357:1121–1135
Weintraub WS, Spertus JA, Kolm P, COURAGE Trial Research Group et al (2008) Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med 359:677–687
Fragasso G, De Cobelli F, Spoladore R, Esposito A, Salerno A, Calori G, Montanaro C, Maranta F, Lattuada G, Margonato A, Del Maschio A, Perseghin G (2011) Resting cardiac energy metabolism is inversely associated with heart rate in healthy young adult men. Am Heart J 162:136–141
Wallhaus TR, Taylor M, DeGrado TR, Russell DC, Stanko P, Nickles RJ, Stone CK (2001) Myocardial free fatty acid and glucose use after Carvedilol treatment in patients with congestive heart failure. Circulation 103:2441–2446
Vanhoutte PM, Gao Y (2013) Beta blockers, nitric oxide, and cardiovascular disease. Curr Opin Pharmacol. doi:10.1016/j.coph.2012.12.002
Fox K, Ford I, Steg PG, Steg PG, Tendera M, Ferrari R (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372:807–816
Bertomeu-Gonzalez V, Bouzas-Mosquera A, Kaski JC (2006) Role of trimetazidine in management of ischemic cardiomyopathy. Am J Cardiol 98:19J–24J
Fragasso G, Rosano G, Baek SH, Sisakian H, Di Napoli P, Alberti L, Calori G, Kang SM, Sahakyan L, Sanosyan A, Vitale C, Marazzi G, Margonato A, Belardinelli R (2013) Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study. Int J Cardiol 163:320–325
Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, Calori G, Alfieri O, Margonato A (2006) A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 48:992–998
Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G, Scifo P, Calori G, Del Maschio A, Margonato A (2006) Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 27:942–948
Nash DT, Nash SD (2008) Ranolazine for chronic stable angina. Lancet 372:1335–1341
Nissen SE, Tuzcu EM, Schoenhagen P (2005) Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352:29–38
Haude M, Erbel R, Erne P, Erne P, Verheye S, Degen H, Böse D, Vermeersch P, Wijnbergen I, Weissman N, Prati F, Waksman R, Koolen J (2013) Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet 381:836–844
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Wien
About this chapter
Cite this chapter
Slavich, M., Kaski, J.C. (2014). Atherosclerotic Heart Disease. In: Lammert, E., Zeeb, M. (eds) Metabolism of Human Diseases. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0715-7_36
Download citation
DOI: https://doi.org/10.1007/978-3-7091-0715-7_36
Published:
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-0714-0
Online ISBN: 978-3-7091-0715-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)